Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBITDA: 2019-2025

Historic EBITDA for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to -$7.1 million.

  • Biodesix's EBITDA rose 17.93% to -$7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.6 million, marking a year-over-year increase of 6.23%. This contributed to the annual value of -$34.5 million for FY2024, which is 16.55% up from last year.
  • Latest data reveals that Biodesix reported EBITDA of -$7.1 million as of Q3 2025, which was up 27.45% from -$9.7 million recorded in Q2 2025.
  • Biodesix's EBITDA's 5-year high stood at -$5.6 million during Q1 2021, with a 5-year trough of -$16.4 million in Q1 2023.
  • Over the past 3 years, Biodesix's median EBITDA value was -$8.6 million (recorded in 2024), while the average stood at -$9.2 million.
  • As far as peak fluctuations go, Biodesix's EBITDA slumped by 340.22% in 2021, and later soared by 50.54% in 2023.
  • Over the past 5 years, Biodesix's EBITDA (Quarterly) stood at -$11.7 million in 2021, then dropped by 18.93% to -$13.9 million in 2022, then soared by 50.54% to -$6.9 million in 2023, then grew by 3.22% to -$6.6 million in 2024, then climbed by 17.93% to -$7.1 million in 2025.
  • Its EBITDA was -$7.1 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$9.1 million in Q1 2025.